precisionmedicineonline8h
FDA Approves Astellas' Vyloy, Chemo in First-Line CLDN18.2-Positive Gastric Cancer With Roche CDx
Vyloy is the first CLDN 18.2-targeted treatment to reach the US market alongside Roche's Ventana CLDN18 RxDx Assay for identifying eligible patients.
precisionmedicineonline11h
CHMP Recommends Approving Kisqali as Adjuvant Treatment for Early-Stage HER2-Negative Breast Cancer
The European Commission is expected to make a decision on Kisqali's approval in this setting in the next two months.
precisionmedicineonline11h
Ontada Using Microsoft's AI Platform to Analyze Unstructured Data to Advance Precision Oncology
The firms aim to use Azure AI to process clinical notes, lab tests, genomic data, images, and other often inaccessible data to identify personalized treatments.
precisionmedicineonline12h
Tenaya Therapeutics Expands Eligibility in Hypertrophic Cardiomyopathy Gene Therapy Trial
The company, which recently completed dosing TN-201 in an initial cohort of patients in the Phase Ib/II trial, will advance the study to the next dosing cohort.
precisionmedicineonline12h
InformedDNA to Offer Phenomix Sciences' Obesity Test
The test is designed to identify various obesity phenotypes that doctors can use to personalize treatment plans.